Caitlyn M Hollingshead, Ana E Khazan, Justin H Franco, Jacob A Ciricillo, Michael N Haddad, Julia T Berry, Joel A Kammeyer
INTRODUCTION: Infectious diseases (ID) consultations have been demonstrated to improve patient outcomes in the treatment of severe infections. However, ID consultation is often unavailable to patients that live in rural communities. Little is known regarding the treatment of infections in rural hospitals with no coverage from an ID specialist. We characterized the outcomes of patients cared for in hospitals without coverage from an ID physician. METHODS: Patients aged 18 years or older admitted to eight community hospitals without access to ID consultation during a 6...
May 27, 2023: Infectious Diseases and Therapy
Lianne Barnieh, Rachel Beckerman, Sushanth Jeyakumar, Alice Hsiao, James Jarrett, Robert L Gottlieb
INTRODUCTION: In addition to significant morbidity and mortality, the coronavirus disease (COVID-19) has strained health care systems globally. This study investigated the cost-effectiveness of remdesivir + standard of care (SOC) for hospitalized COVID-19 patients in the USA. METHODS: This cost-effectiveness analysis considered direct and indirect costs of remdesivir + SOC versus SOC alone among hospitalized COVID-19 patients in the US...
May 24, 2023: Infectious Diseases and Therapy
Oscar Herrera-Restrepo, Yuting Kuang, John D'Angelo, Rafik Bekkat-Berkani, Diana E Clements, Jennifer Uyei
We conducted a targeted literature review to understand the determinants of meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal serogroup B (MenB) vaccination coverage and adherence to vaccination schedules in the USA, and to identify evidence to support improvement of MenACWY and MenB vaccination coverage and adherence in older adolescents. Sources published since 2011 were considered, with sources published since 2015 given preference. Out of 2355 citations screened, 47 (46 studies) were selected for inclusion...
May 22, 2023: Infectious Diseases and Therapy
Antonio C Arrieta, Adam Lee, M Tuan Tran
Incidence of invasive mold infections in children, while rare, is increasing as the population of high-risk patients expands, including premature infants, pediatric patients undergoing treatment for hematological malignancies, or recipients of allogeneic hematologic stem cell transplants. The infectious agents, including Aspergillus spp., Mucorales, and other molds, are especially difficult to treat and have serious morbidity and high mortality. Clinicians must maintain a high index of suspicion for invasive mold infections in at-risk patients...
May 20, 2023: Infectious Diseases and Therapy
Rui-Ting Liu, Yan Chen, Shan Li, Xi-Xi Wan, Li Weng, Jin-Min Peng, Bin Du
INTRODUCTION: Invasive pulmonary aspergillosis (IPA) is a common infection in intensive care units (ICUs). There are no consensus criteria for defining IPA in the ICU. We aimed to compare the diagnosis and prognosis performances of three criteria (the 2020 EORTC/MSG criteria, the 2021 EORTC/MSG ICU criteria, the modified AspICU criteria (M-AspICU)) for IPA in the ICU. METHODS: In this retrospective study from our single center, we applied the three different criteria for IPA in patients with suspected pneumonia and undergoing at least one mycological test between November 10, 2016 and November 10, 2021...
May 18, 2023: Infectious Diseases and Therapy
Erika Asperges, Giuseppe Albi, Valentina Zuccaro, Margherita Sambo, Teresa C Pieri, Matteo Calia, Marta Colaneri, Laura Maiocchi, Federica Melazzini, Angioletta Lasagna, Andrea Peri, Francesco Mojoli, Paolo Sacchi, Raffaele Bruno
INTRODUCTION: The hyperinflammation phase of severe SARS-CoV-2 is characterised by complete blood count alterations. In this context, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) can be used as prognostic factors. We studied NLR and PLR trends at different timepoints and computed optimal cutoffs to predict four outcomes: use of continuous positive airways pressure (CPAP), intensive care unit (ICU) admission, invasive ventilation and death. METHODS: We retrospectively included all adult patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia admitted from 23 January 2020 to 18 May 2021...
May 17, 2023: Infectious Diseases and Therapy
Didier Pinquier, Pascal Crépey, Pierre Tissières, Astrid Vabret, Jean-Christophe Roze, François Dubos, Fabienne Cahn-Sellem, Etienne Javouhey, Robert Cohen, Catherine Weil-Olivier
No abstract text is available yet for this article.
May 13, 2023: Infectious Diseases and Therapy
Christianne Micallef, Anita H Sung, Maria Gheorghe, Rahael Maladwala, Kate Grady, Christian Kouppas, David A Enoch
INTRODUCTION: Antifungal stewardship (AFS) programs are recognized to contribute to optimizing antifungal prescribing for treatment and prophylaxis. However, only a small number of such programs are implemented. Consequently, evidence on behavioral drivers and barriers of such programs and learnings from existing successful AFS programs is limited. This study aimed to leverage a large AFS program in the UK and derive learnings from it. The objective was to (a) investigate the impact of the AFS program on prescribing habits, (a) use a Theoretical Domains Framework (TDF) based on the COM-B (Capability, Opportunity, and Motivation for Behavior) to qualitatively identify drivers and barriers for antifungal prescribing behaviors across multiple specialties, and (c) semiquantitatively investigate trends in antifungal prescribing habits over the last 5 years...
May 13, 2023: Infectious Diseases and Therapy
Yu Hwa Choi, Young Ae Kang, Kwang Joo Park, Jae Chol Choi, Kwan Goo Cho, Da Yeon Ko, Jun Ho Ahn, Boram Lee, Eunsol Ahn, Yun Ju Woo, Kwangsoo Jung, Nan Yul Kim, Valerie A Reese, Sasha E Larsen, Susan L Baldwin, Steven G Reed, Rhea N Coler, Hyejon Lee, Sang-Nae Cho
INTRODUCTION: This randomized, double-blind, placebo-controlled, phase 2a trial was conducted to evaluate the safety and immunogenicity of the ID93 + glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) vaccine in human immunodeficiency virus (HIV)-negative, previously Bacillus Calmette-Guérin (BCG)-vaccinated, and QuantiFERON-TB-negative healthy adults in South Korea. METHODS: Adults (n = 107) with no signs or symptoms of tuberculosis were randomly assigned to receive three intramuscular injections of 2 μg ID93 + 5 μg GLA-SE, 10 μg ID93 + 5 μg GLA-SE, or 0...
May 11, 2023: Infectious Diseases and Therapy
Julio Ramirez, Ruth Carrico, Ashley Wilde, Alan Junkins, Stephen Furmanek, Thomas Chandler, Paul Schulz, Robin Hubler, Paula Peyrani, Qing Liu, Sonali Trivedi, Sonal Uppal, Warren V Kalina, Ann R Falsey, Edward E Walsh, Kari Yacisin, Luis Jodar, Bradford D Gessner, Elizabeth Begier
INTRODUCTION: Nearly all existing respiratory syncytial virus (RSV) incidence estimates are based on real-time polymerase chain reaction (RT-PCR) testing of nasal or nasopharyngeal (NP) swabs. Adding testing of additional specimen types to NP swab RT-PCR increases RSV detection. However, prior studies only made pairwise comparisons and the synergistic effect of adding multiple specimen types has not been quantified. We compared RSV diagnosis by NP swab RT-PCR alone versus NP swab plus saliva, sputum, and serology...
May 6, 2023: Infectious Diseases and Therapy
Dayu Chen, Bo Wen, Xuanyu Wu, Xinxin Zheng, Huaijun Zhu, Xingkai Chen, Dan Han, Jinchun Liu, Yunxing Liu, Jiayue Guo, Shaoshi Zhu, Haozhen Ren, Weihong Ge, Haixia Zhang
INTRODUCTION: Pharmacist-driven (PD) dosing and monitoring services have been shown to improve the clinical and economic outcomes in patients treated with different antibiotics, other than teicoplanin. This study investigates the impact of PD dosing and monitoring services on the clinical and economic outcomes of non-critically ill patients receiving teicoplanin treatment. METHODS: A single-center retrospective study was conducted. Patients were divided into the PD group and the non-PD (NPD) group...
May 4, 2023: Infectious Diseases and Therapy
Hexiang Zheng, Yu Geng, Changgui Gu, Ming Li, Minxin Mao, Yawen Wan, Huijie Yang, Yuxin Chen
INTRODUCTION: Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne virus associated with a high rate of mortality, as well as encephalitis. We aim to develop and validate a machine learning model to early predict the potential life-threatening conditions of SFTS. METHODS: The clinical presentation, demographic information, and laboratory parameters from 327 patients with SFTS at admission in three large tertiary hospitals in Jiangsu, China between 2010 to 2022 are retrieved...
May 3, 2023: Infectious Diseases and Therapy
Wei-Chen Tai, Shih-Cheng Yang, Chih-Chien Yao, Cheng-Kun Wu, An-Che Liu, Chen-Hsiang Lee, Yuan-Hung Kuo, Seng-Kee Chuah, Chih-Ming Liang
INTRODUCTION: High-dose dual therapy (HDDT) can attain acceptable eradication rates provided that the optimal doses, timing and treatment duration are applied. The existing evidence still shows inconsistent reports (< 90%) on HDDT therapy except in some Asian countries. We aimed to assess and compare the efficacy of 14-day HDDT by comparing it to 14-day rabeprazole-containing hybrid therapy (HT) and to investigate the host and bacterial factors predicting the treatment outcomes of eradication therapies...
May 3, 2023: Infectious Diseases and Therapy
Tomer Hoffman, Or Kriger, Shoshana Cohen, Shiraz Gefen-Halevi, Dafna Yahav, Sharon Amit
INTRODUCTION: Microbiological diagnosis is central for adequate treatment of bone and joint infections. Culture-based methods have a limited diagnostic sensitivity and a long turnaround time (TAT). The objective of this study was to compare the diagnostic performance of BioFire Joint Infection Panel Investigational Use Only version (hereafter BioFire)-a sample-to-result multiplex PCR panel-with culture-based methods and 16S ribosomal RNA (rRNA) PCR and sequencing, when available. METHODS: This study presents a retrospective analysis of a prospective validation study of the BioFire panel...
May 2, 2023: Infectious Diseases and Therapy
Pete Schmidt, Jean Gong, Kristin Narayan, Deepali Gupta, Frank Engler, Yong Li, Amanda Copans, Ed Campanaro
INTRODUCTION: Adintrevimab is a fully human immunoglobulin G1 extended half-life monoclonal antibody that was developed to have broad neutralization against SARS-CoV, SARS-CoV-2, and other SARS-like CoVs with pandemic potential. Here we report the safety, pharmacokinetics (PK), serum viral neutralizing antibody (sVNA) titers, and immunogenicity results of the first three cohorts evaluated in the first-in-human study of adintrevimab in healthy adults. METHODS: This is a phase 1, randomized, placebo-controlled, single ascending-dose study of adintrevimab administered intramuscularly (IM) or intravenously (IV) to healthy adults aged ≥ 18-55 years with no current or prior SARS-CoV-2 infection...
April 25, 2023: Infectious Diseases and Therapy
Júlia Spinardi, Ana Carolina Dantas, Carolina Carballo, Karan Thakkar, Nadine Al Akoury, Moe Hein Kyaw, Graciela Del Carmen Morales Castillo, Amit Srivastava, Marco Aurélio P Sáfadi
The rapid rollout of vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic over the past 2 years has resulted in the use of various vaccine platforms and regional differences in COVID-19 vaccine implementation strategies. The aim of this narrative review was to summarize evolving COVID-19 vaccine recommendations in countries in Latin America, Asia, and Africa and the Middle East across various vaccine platforms, age groups, and specific subpopulations. Nuances in primary and booster vaccination schedules were evaluated, and the preliminary impact of such diverse vaccination strategies are discussed, including key vaccine effectiveness data in the era of Omicron-lineage variants...
April 25, 2023: Infectious Diseases and Therapy
Johnna Perdrizet, Emily K Horn, Kyla Hayford, Lindsay Grant, Rachid Barry, Liping Huang, Cheryl McDade, Michele Wilson
INTRODUCTION: This study estimates the annual population-level impact of 13-valent pneumococcal conjugate vaccine (PCV13) infant national immunization programs (NIPs) on vaccine-type and non-vaccine type invasive pneumococcal disease (IPD) incidence across all ages using national surveillance data. METHODS: We identified countries (Australia, Canada, England and Wales, Israel, and the US) with national IPD active surveillance data that introduced the seven-valent PCV (PCV7) followed by PCV13, which also reported annual serotype- and age group-specific incidence...
April 20, 2023: Infectious Diseases and Therapy
Mona Al Dabbagh, Mohammad Alghounaim, Rana H Almaghrabi, Ghassan Dbaibo, Ghassan Ghatasheh, Hanan M Ibrahim, Mohamed Abdel Aziz, Ashraf Hassanien, Naglaa Mohamed
INTRODUCTION: Gram-negative bacteria (GNB) have become prominent across healthcare and community settings due to factors including lack of effective infection control and prevention (ICP) and antimicrobial stewardship programs (ASPs), GNB developing antimicrobial resistance (AMR), and difficulty treating infections. This review summarizes available literature on healthcare-associated infections (HAIs) in Middle Eastern pediatric patients. METHODS: Literature searches were performed with PubMed and Embase databases...
April 18, 2023: Infectious Diseases and Therapy
Takeji Umemura, Kittima Wattanakamolkul, Yoshikazu Nakayama, Yasushi Takahashi, Urbano Sbarigia, Lim KyungHwa, Angelina Villasis-Keever, Martina Furegato, Laurène Gautier, Gregoire Nowacki, Jessica Azzi, David Bin-Chia Wu
INTRODUCTION: Chronic hepatitis B (CHB) is one of the world's major healthcare problems, especially in the Western Pacific regions. This study describes the prevalence, incidence, treatment profiles and clinical and economic burden of chronic hepatitis B patients in Japan using the Japan Medical Data Center (JMDC) Claims Database. METHODS: This is a retrospective observational study. Prevalence cases were identified as patients with ≥ 1 inpatient or ≥ 2 outpatient CHB diagnoses and ≥ 2 records for hepatitis B tests or ≥ 1 prescription for CHB treatment between January 2010 and December 2019...
April 17, 2023: Infectious Diseases and Therapy
Olivia Dybro Baek, Camilla K Hjermitslev, Line Dyreborg, Simon M D Baunwall, Katrine L Høyer, Nina Rågård, Lianna H Hammeken, Johan V Povlsen, Lars H Ehlers, Christian Lodberg Hvas
INTRODUCTION: The use of faecal microbiota transplantation (FMT) to eradicate intestinal carriage of multidrug-resistant organisms (MDRO) has been described in case reports and small case series. Although few in numbers, these patients suffer from recurrent infections that may exacerbate both the patients' comorbidities and their healths. In the current study, we hypothesized that FMT for MDRO-related urinary tract infections (UTIs) reduces hospitalisations and associated costs. METHODS: In a cohort of patients referred for FMT from 2015 to 2020, we selected all patients who had consecutively been referred for eradication of MRDO carriage with UTIs...
April 16, 2023: Infectious Diseases and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.